• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

6.370 +1.210 (+23.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,148,102
Open 5.250
Bid (Size) 6.350 (600)
Ask (Size) 6.410 (100)
Prev. Close 5.160
Today's Range 5.230 - 6.450
52wk Range 4.338 - 7.250
Shares Outstanding 28,919,810
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
March 17, 2026
From Candel Therapeutics
Via GlobeNewswire

Performance

YTD
+17.1%
+17.1%
1 Month
+29.7%
+29.7%
3 Month
+7.6%
+7.6%
6 Month
+15.0%
+15.0%
1 Year
+41.2%
+41.2%

More News

Read More
News headline image
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 12, 2026
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer ↗
October 14, 2025
Via Stocktwits
News headline image
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
March 09, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
February 24, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Pricing of Public Offering
February 19, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today ↗
February 19, 2026
Via Stocktwits
News headline image
Candel Therapeutics Announces Proposed $100 Million Public Offering
February 19, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
February 19, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
February 11, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗
December 05, 2025
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
November 17, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 13, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
November 04, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
November 03, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards ↗
October 23, 2025
Via Benzinga
News headline image
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
October 16, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
October 14, 2025
Via Benzinga
News headline image
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
October 14, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
October 14, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
October 03, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
September 29, 2025
From Candel Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Candel Therapeutics, Inc. - Common Stock publicly traded?
Yes, Candel Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Candel Therapeutics, Inc. - Common Stock trade on?
Candel Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Candel Therapeutics, Inc. - Common Stock?
The ticker symbol for Candel Therapeutics, Inc. - Common Stock is CADL on the Nasdaq Stock Market
What is the current price of Candel Therapeutics, Inc. - Common Stock?
The current price of Candel Therapeutics, Inc. - Common Stock is 6.370
When was Candel Therapeutics, Inc. - Common Stock last traded?
The last trade of Candel Therapeutics, Inc. - Common Stock was at 04/17/26 04:00 PM ET
What is the market capitalization of Candel Therapeutics, Inc. - Common Stock?
The market capitalization of Candel Therapeutics, Inc. - Common Stock is 184.22M
How many shares of Candel Therapeutics, Inc. - Common Stock are outstanding?
Candel Therapeutics, Inc. - Common Stock has 184M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap